W. L. Gore & Associates (Gore) announced that interim results from multi-year, multi-center studies using the GORE PROPATEN Vascular Graft were presented recently at the 34th Annual VEITHsymposium™ in New York. The GORE PROPATEN Device is the first device with an ePTFE-heparin combination that is designed to reduce thrombosis (clotting), a common cause of graft failure. The average one-year primary patency from all the reported literature on the GORE PROPATEN Vascular Graft in below-knee bypasses has been reported to be 80 percent.
